Cholinergic agonism for the treatment of pancreatic cancer
View Patent ↗The invention provides for methods for treating pancreatic cancer, reducing or inhibiting pancreatic tumor cells, inhibiting or treating pancreatic cancer metastases, and inhibiting pancreatic cancer stem cell growth in a subject by administering a cholinergic agonist.
1. A method for treating pancreatic cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of cholinergic agonist to the subject in need thereof, wherein the cholinergic agonist is a M3 receptor agonist or a cholinergic muscarinic receptor 1 (CHRM1) agonist.
2. The method of claim 1 , wherein the cholinergic agonist is a M3 receptor agonist.
3. The method of claim 1 , wherein the cholinergic agonist is a cholinergic muscarinic receptor 1 (CHRM1) agonist.
4. The method of claim 3 , wherein the cholinergic muscarinic receptor 1 (CHRM1) agonist is McN-34A.
5. The method of claim 1 , further comprising administering a cytotoxic therapy.
6. The method of claim 5 , wherein the cytotoxic therapy is gemcitabine, nab-paclitaxel, or a combination thereof.
7. The method of claim 3 , further comprising administering a cytotoxic therapy.
8. The method of claim 7 , wherein the cytotoxic therapy is gemcitabine, nab-paclitaxel, or a combination thereof.
9. The method of claim 1 , further comprising performing a resection surgery, a Whipple surgery, or a distal pancreatectomy.
10. The method of claim 9 , wherein the cholinergic agonist is administered before, during, or after the resection surgery, the Whipple surgery, or the distal pancreatectomy is performed.
11. The method of claim 1 , wherein the cholinergic agonist is administered before, during, or after a resection surgery, a Whipple surgery, or a distal pancreatectomy.
12. The method of claim 3 , further comprising performing a resection surgery, a Whipple surgery, or a distal pancreatectomy.
13. The method of claim 12 , further comprising administering a cytotoxic therapy.
14. The method of claim 13 , wherein the cytotoxic therapy is gemcitabine, nab-paclitaxel, or a combination thereof.
15. The method of claim 1 , wherein the pancreatic cancer is pancreatic adenocarcinoma (PDAC).
16. The method of claim 15 , wherein the PDAC is Grade 1 or Grade 2A PDAC.
17. The method of claim 11 , wherein the subject is administered 200 mg of bethanechol per day for at least 14 days prior to the resection surgery, Whipple surgery, or distal pancreatectomy.
18. The method of claim 11 , wherein the subject is administered 30 mg of pilocarpine per day prior to the resection surgery, Whipple surgery, or distal pancreatectomy.
19. The method of claim 4 , wherein the subject is administered 50 mg of McN-34A per day.
20. The method of claim 4 , wherein the subject is administered 100 mg of McN-34A per day.
21. The method of claim 4 , wherein the subject is administered 200 mg of McN-34A per day.
22. The method of claim 11 , wherein the subject is administered 200 mg of McN-34A per day prior to the resection surgery, Whipple surgery, or distal pancreatectomy.
23. The method of claim 1 , wherein the subject has metastatic pancreatic cancer.
24. The method of claim 6 , wherein the cytotoxic therapy is gemcitabine and nab-paclitaxel.
25. The method of claim 8 , wherein the cytotoxic therapy is gemcitabine and nab-paclitaxel.
26. The method of claim 14 , wherein the cytotoxic therapy is gemcitabine and nab-paclitaxel.
27. The method of claim 9 , further comprising administering a cytotoxic therapy.
28. The method of claim 27 , wherein the cytotoxic therapy is gemcitabine, nab-paclitaxel, or a combination thereof.
29. The method of claim 28 , wherein the cytotoxic therapy is gemcitabine and nab-paclitaxel.